Facilitating development of and ensuring future access to innovative drug formulations and delivery mechanisms New paradigms on ART (Tuesday 23 July, 14:30.

Slides:



Advertisements
Similar presentations
February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
Advertisements

Consultative expert working group - proposals Barcelona
Gilead’s Tech Transfer Partnerships and IP in India
The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.
UNITAID Innovative Financing Mechanism  Denis Broun Executive Director.
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
HIV Treatment and Intellectual Property Rights: The Experience of the Medicines Patent Pool Esteban Burrone Melbourne – International AIDS Conference July.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Opportunities & Challenges: Expanding Access to Hepatitis C Treatment Gregg Alton Executive Vice President, Corporate & Medical Affairs.
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Medicines Patent Pool – Strictly Confidential, Not for Circulation Licensing Technology and Intellectual Property for the Development of Paediatric Formulations.
A very short introduction to patents & access to medicines.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Total health ODA commitments, US$ Billions.
UNITAID’s Market Approach in HIV Diagnostics Brenda Waning International AIDS Society 18 July, 2011 Rome.
Access to medicines, WTO TRIPS and Seychelles patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014.
UNITAID The HIV/AIDS Medicines Patent Pool Initiative October 2010.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
DR CHIDI V NWENEKA EXECUTIVE DIRECTOR AFRICAN AIDS VACCINE PARTNERSHIP AAVP and the Promotion of HIV Vaccines in Africa: Supporting Career Development.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
The Medicines Patent Pool Ellen ‘t Hoen UNITAID Consultative Forum Geneva, 4-5 October 2011.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
1 |1 | Treatment 2.0 Catalyzing the Next Phase of Scale-up Gottfried Hirnschall Director, HIV Department WHO, Geneva.
PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
'Hot topics' ESSENTIAL MEDICINES FOR CHILDREN Suzanne Hill September 2006.
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
Page 0 UNITAID  Melbourne, Australia 2014 Overview of paediatric antiretroviral market : is market in shape to enable achieving targets? Carmen Pérez.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.
IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.
Optimizing the Cost and Quality of HIV / AIDS Care and Treatment Anil Soni, Clinton HIV / AIDS Initiative 19 th Board Meeting, Geneva 6 May 2009.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.
PATENT POOL Anand Grover United Nations Special Rapporteur on Health East Africa Consultation, September 2010.
NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.
The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)
VOLUNTARY PATENT POOLING FOR PUBLIC HEALTH A Model For Innovation And Access.
Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,
The HIV Response Where are we now?
Off-label Use.
How Pricing Affects Availability
20:20 Vision Making new and old money work better
MPP LICENCES AND OPPORTUNITIES FOR INTRODUCTION OF NEW PRODUCTS AND FORMULATIONS Esteban Burrone, July 2017.
Generic Competition Universities Allied for Essential Medicines
Accelerating access for optimized regimens
Intellectual Property Protection and Access to Medicines
Zimbabwe’s shift towards treat all: national country context
UNITAID Overview Joint Consultation on Seasonal Malaria Chemoprevention Ouagadougou, Burkina Faso, February 2017.
Making medicines, diagnostics and other commodities more affordable
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
New/Optimal ARV Treatments Why ? & How
Trade-related policies and access to medicines
New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs)  HIV positive.
Accelerating Access to new WHO-Recommended Generic Medicines and Formulations Esteban Burrone and Aastha Gupta Medicines Patent Pool July 2018.
Contents Impact in terms of treatment affordability Impact in making new treatments available faster Impact in making needed new formulations.
Generics – what can be done
Setting the Stage for PrEP Where are we now, and where should we go?
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.
Toolkit for research and development of paediatric antiretroviral drugs and formulations In collaboration with experts from the Paediatric Antiretroviral.
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
A glimpse to the future: The ARV pipeline up to how do we ensure it is affordable and acceptable? Helen McDowell Head of Government Affairs & Global.
Every Mother, Every Child: Closing the Gaps in HIV Management
TRANSITION TO TLD – ZIMBABWE REPORT
Share your thoughts on this presentation with #IAS2019
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Facilitating development of and ensuring future access to innovative drug formulations and delivery mechanisms New paradigms on ART (Tuesday 23 July, 14:30 - 16:00) http://programme.ias2019.org/Programme/Session/2 In this session, the speakers will address new and future ways of delivering of ART and its relevance for PLHIV. The speakers will address: controversies on dual versus triple therapy; how to identify post-treatment controllers; the role of long-acting injectable devices; and approaches to control immune activation  Introduction (Pedro Cahn, Fundación Huesped, Argentina) 14:30 Dual versus Triple ART, what to use to start? (Roy Gulick, Weill Cornell Medicine, United States) 14:40 Injectables and implanting devices: Pro versus cons? (Chloe Orkin, Royal London Hospital - BHIVA, United Kingdom ) 14:55 Therapeutic approaches to control HIV immune activation (Michaela Mueller-Trutwin, Institut Pasteur, France) 15:10 ART Rapid start, when, why, for whom? (Serena Koenig, Brigham and Women's Hospital, United States) 15:15 Facilitating development of and ensuring future access to innovative drug formulations and delivery mechanisms (Charles Gore, Medicines Patent Pool, Switzerland) 15:40 Closing remarks (Pedro Cahn, Fundación Huesped, Argentina) 15:50 Charles Gore Executive Director Medicines Patent Pool Presentation at IAS 2019 Session “New paradigms on ART” Tuesday, 23 July 2019, Mexico City (Mexico)

Declaration of interest I declare no conflicts of interest. MPP activities in HIV, HCV, TB and the long-acting space are funded by Unitaid. MPP expansion into patented essential medicines is undertaken with financial support from the Swiss Agency for Development and Cooperation and the Wellcome Trust.

The MPP as a mechanism to Facilitate development and access to medicines Introduction o   Overview of the MPP model   Role of the MPP in new paradigms on ART: innovative drug formulations and delivery mechanisms o   MPP work that has enabled early access to innovative drugs (e.g., DTG) o   MPP work that has facilitated the development of innovative drug formulations (e.g., FDCs - TLD, paediatrics) o   Facilitating development of and access to dual therapy formulations (e.g., DTG/3TC) o   Facilitating development of and access to long-acting formulations (medicines and delivery mechanisms) Next steps: MPP work in the long-acting space o   MPP/Unitaid Intellectual Property Report on Long-Acting Technologies o   Unitaid funded Collaboration hub for long-acting technologies o   Role in future licensing of innovative drug formulations and delivery mechanisms

> > > MPP model: How we work ROYALTIES The MPP negotiates public-health driven licences with patent holders. > > > The MPP sublicenses drugs to generic companies. Licensing terms encourage the sale of affordable generic versions in developing countries. PATENT HOLDERS GENERIC MANUFACTURERS PEOPLE LIVING IN LOW- AND MIDDLE-INCOME COUNTRIES

MPP Model: Public-health oriented licences Wide geographical scope Flexibility to combine different medicines & develop fixed-dose combinations Strict quality assurance policies Non-exclusive to encourage competition Compatibility with other access policies and strategies Public disclosure of company patent information Transparent: terms of licences published Licence management to monitor compliance and prevent market leakage

Role of the MPP in new paradigms on ART: innovative drug formulations

Facilitating development and Early access to innovative formulations Within 5 years of FDA approval of DTG, new combination TLD developed, approved and supplied to 2.7 million people 2013 2014 2016 AUGUST US FDA approval DTG as HIV treatment APRIL MPP signs licence for DTG with ViiV Healthcare JUNE WHO recommends DTG as part of first-line HIV treatment 2017 2018 AUGUST US FDA approves TLD from first MPP licensee SEPTEMBER CHAI et al price of TLD approx. 75 USD/person/year JUNE Six generics ready to supply TLD DECEMBER TLD supplied in 26 countries, serving 2.7 million PLHIV MPP work that has facilitated the development of innovative drug formulations (e.g., FDCs - TLD, paediatrics) ----- DTG-based regimens have been identified as important future first- line therapies for both children and adults by the WHO Conferences on Antiretroviral Drug Optimization, and eventually entered the 2018 WHO Interim HIV Guidelines as first-line regimen for adults, children and infants. DTG 50mg tablet is currently approved for use in adults as well as children weighing at least 40kg in combination with appropriate reverse-transcriptase inhibitors (RTI) backbones. It could also be added to a DTG-based regimen in case of drug-drug interaction with rifampin, which is frequently used in treating TB co-infections. DTG 50mg is included in the President’s Emergency Plan for AIDS Relief (PEPFAR) List of Priority ARV Formulations as of 2018. TDF + 3TC (or FTC) + DTG is a once-daily, single-tablet regimen that has been recommended by WHO in 2018 as the preferred first-line treatment for adults and adolescents living with HIV. Likewise, the regimen has also been recommended for use in HIV post-exposure prophylaxis. TLD is included in the PEPFAR List of Priority ARV Formulations as of 2018. TLD already approved in 22 countries Filed in further 21 countries Supplied in 37 countries Latest TLD (300/300/50 mg) data from March 2019

Facilitating development and Early access to innovative formulations TAF/FTC/DTG New combination identified as potential future first-line treatment by the WHO Conference on Antiretroviral Drug Optimization (CADO 3) Flexibility to combine different medicines to develop FDCs Combines molecules from two different patent holders into single fixed dose combination Developed in record time. USFDA approval from one manufacturer, filed by one other and under development by several other MPP licensees So far, has been filed in 8 countries for regulatory approval, approved in 4 countries and many more planned in the coming months MPP work that has facilitated the development of innovative drug formulations (e.g., FDCs - TLD, paediatrics) ----- TAF + FTC (or 3TC) + DTG has been identified as a potential future first-line treatment by the WHO Conferences on Antiretroviral Drug Optimization (CADO2, 3) as well as other stakeholder forums. TAF is believed to have safety advantages over its predecessor TDF, and could enable further cost saving. The TAF/FTC/DTG regimen, taken once daily, is currently being studied in major phase 3 studies such as ADVANCE and VESTED, and this regimen has been included in the PEPFAR Watchlist of Priority ARV Formulations as of 2018. Latest TAF/FTC/DTG (25/200/50 mg) data from March 2019

Role of the MPP in new paradigms on ART: innovative delivery mechanisms Long-acting technology space

Long acting technologies: Intellectual property landscape Long-acting technologies MPP/Unitaid report on the patent landscape for long-acting technologies with potential impact for preventing or treating major diseases in low- and middle-income countries Available at https://bit.ly/2xOrGiK MPP/Unitaid Intellectual Property Report on Long-Acting Technologies

Long acting technologies: Findings from IP landscape analysis LA technologies often have multi-layered protections on the molecule, the formulation, the delivery device, and the process of manufacturing, potentially providing additional years of exclusivity for the LA product. Patented platform technologies can be applied to multiple products. Frequently a licence is granted to a specific product using such technology, rather than to the entire platform. Geographical coverage of patent filings often varies by product/technology. Smaller corporations and academic institutions tend to file in less LMICs compared with major pharmaceutical companies. Key manufacturing countries (e.g., India and China) are often covered.

Long acting technologies: Long-acting Technology Access Hub The MPP is entering an exploratory phase to determine whether, and how, the MPP model can be applied to facilitate the development of long-acting formulations of public health importance in LMICs The MPP is proposing to establish a Long-acting Technology Access Hub Seeking commitments for collaboration /licensing on development of priority products and technologies Expanding access to drug/device/delivery platform combinations of emerging long-acting products Facilitating information sharing to maximize potential of long- acting pipeline for LMICs Working closely with existing initiatives that are active in the long acting space This exploratory phase is supported by Unitaid Unitaid funded Collaboration hub for long-acting technologies

Long acting technologies: Examples of patent pooling Supporting development of and access to the most optimal medicine/platform pair (ILLUSTRATIVE ONLY) GLE/PIB (G/P) TAF, FTC, DTG, BIC CAB, EfDA, GS-CA2, LA injectables HCV For for one-shot cure Malaria For prophylaxis HIV For PrEP or treatment TB For DR-TB and LTBI treatment or preventing transmission AMR One-shot new antibiotics for good stewardship BDQ, DLM, others Atovaquone, Ivermectin Medicines Platforms (Licences would likely be product-specific) Removable depots HIV For PrEP or treatment maintenance HBV Current treatments and future functional cures Malaria For vector control LA injectables Product development by partners Depots – biodegradable Facilitating development of and access to long-acting formulations (medicines and delivery mechanisms) LA orals Depots – non-biodegradable Malaria For vector control HIV For PrEP LA orals Microneedle patches (MAPs) Microneedle patches (MAPs) HIV Treatment or PrEP. For neonatal prophylaxis + Other patents that could hinder freedom to operate + other disease areas that could benefit from LA/ER

Take-home messages

Take-home messages: New paradigms on Access-oriented licensing Access-oriented licensing can support new ART approaches, including new paradigms: Facilitating the development and access to new triple-therapy combinations (e.g. TLD, TAF/FTC/DTG) Facilitating access to new dual therapies (e.g., DTG/3TC) Facilitating development of and access to long-acting formulations (medicines and delivery mechanisms) “To avoid the pitfalls the past, when new medicines were introduced first in high-income countries and only much later in LMICs, we need to be thinking ahead of the curve to prepare for a healthy market and prompt access to these game-changing long-acting tools” Lelio Marmora Executive Director, Unitaid The MPP looks forward to working with all stakeholders in the emerging long-acting space. Source: MPP 2018 Annual Report: Expanding Access to Public Health

Thank you! WWW.medicinespatentpool.org www.medspal.org @MedsPatentPool Contact details Charles Gore Executive Director cgore@medicinespatentpool.org Sandra Nobre Business Development Director snobre@medicinespatentpool.org Esteban Burrone Head of Policy eburrone@medicinespatentpool.org Sébastien Morin Policy and Advocacy Manager smorin@medicinespatentpool.org